miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1

Ye Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yunpeng Liu(Shenyang Institute of Automation), Xiaofang Che(First Hospital of China Medical University), Xiujuan Qu(First Hospital of China Medical University), Ximing Wang(Shandong University), Ce Li(Affiliated Hospital of Hebei University), Xuejun Hu(First Hospital of China Medical University), Ying Cai(Shanghai Jiao Tong University), Yibo Fan(The University of Texas MD Anderson Cancer Center)
Tumor Biology
November 19, 2014
10.1007/s13277-014-2835-7
Cited by 68

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417